FDA clears Protagonist Therapeutics ICOTYDE as first-line oral plaque psoriasis treatment

FDA clears Protagonist Therapeutics ICOTYDE as first-line oral plaque psoriasis treatment
Protagonist Therapeutics wins FDA nod

Protagonist Therapeutics received U.S. FDA approval for ICOTYDE (icotrokinra) as a new oral peptide therapy for plaque psoriasis.

ICOTYDE is the first targeted oral peptide option approved for first-line systemic treatment of this chronic skin condition. The company credited its science platform, research team, Johnson & Johnson, clinical investigators, and patients for supporting the breakthrough. The approval marks a significant advance in expanding treatment options for people living with plaque psoriasis.

ICOTYDE’s approval further highlights the progress driven by Protagonist Therapeutics’ pioneering peptide technology, a foundation the company notably detailed in its previous showcase of its innovative platform. This development underscores the expanding role of peptide-based therapies in addressing complex medical needs.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.